| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The FASEB Journal, Vol 7, 872-879, Copyright © 1993 by The Federation of American Societies for Experimental Biology
REVIEWS |
K Vousden
Ludwig Institute for Cancer Research, St. Mary's Hospital Medical School, London.
Human papillomaviruses (HPVs) contribute to the development of almost all cervical cancers, a common and often fatal human disease. The mechanisms by which the HPVs function in malignant progression appear to be related to the activity of the two viral oncoproteins, E6 and E7, which form complexes with several cell proteins normally involved in controlling cell growth. Of particular interest has been the association of E6 with p53 and E7 with Rb, both products of tumor suppressor genes. Expression of E6 and E7 is likely to overcome the regulation of cell proliferation normally mediated by proteins like p53 and Rb, allowing uncontrolled growth and providing the potential for malignant transformation. These activities of E6 and E7 support the importance of the tumor suppressor proteins in the maintenance of normal cell proliferation and provide novel approaches to understanding the mechanisms by which they function.
This article has been cited by other articles:
|
|
 |
|
  X. Wang, A.-B. Moscicki, L. Tsang, A. Brockman, and M. Nakagawa Memory T Cells Specific for Novel Human Papillomavirus Type 16 (HPV16) E6 Epitopes in Women Whose HPV16 Infection Has Become Undetectable Clin. Vaccine Immunol., June 1, 2008; 15(6): 937 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L-W Huang, S-L Chao, and B-H Lee Integration of human papillomavirus type-16 and type-18 is a very early event in cervical carcinogenesis J. Clin. Pathol., May 1, 2008; 61(5): 627 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Courtete, A.-P. Sibler, G. Zeder-Lutz, D. Dalkara, M. Oulad-Abdelghani, G. Zuber, and E. Weiss Suppression of cervical carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6 antibody and small interfering RNA Mol. Cancer Ther., June 1, 2007; 6(6): 1728 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Lea, N. Sunaga, M. Sato, G. Kalahasti, D. S. Miller, J. D. Minna, and C. Y. Muller Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells Reproductive Sciences, January 1, 2007; 14(1): 20 - 28. [Abstract] [PDF]
|
|
|
|
 |
|
 D. N. Shepherd, D. P. Martin, D. R. McGivern, M. I. Boulton, J. A. Thomson, and E. P. Rybicki A three-nucleotide mutation altering the Maize streak virus Rep pRBR-interaction motif reduces symptom severity in maize and partially reverts at high frequency without restoring pRBR-Rep binding J. Gen. Virol., March 1, 2005; 86(3): 803 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Glahder, C. N. Hansen, J. Vinther, B. S. Madsen, and B. Norrild A promoter within the E6 ORF of human papillomavirus type 16 contributes to the expression of the E7 oncoprotein from a monocistronic mRNA J. Gen. Virol., December 1, 2003; 84(12): 3429 - 3441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kothapalli, S. A. Stewart, E. M. Smyth, I. Azonobi, D. J. Rader, E. Pure, and R. K. Assoian Prostacylin Receptor Activation Inhibits Proliferation of Aortic Smooth Muscle Cells by Regulating cAMP Response Element-Binding Protein- and Pocket Protein-Dependent Cyclin A Gene Expression Mol. Pharmacol., August 1, 2003; 64(2): 249 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Schaal, W. G. Mallet, D. L. McMinn, N. V. Nguyen, M. M. Sopko, S. John, and B. S. Parekh Inhibition of human papilloma virus E2 DNA binding protein by covalently linked polyamides Nucleic Acids Res., February 15, 2003; 31(4): 1282 - 1291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Boldt, U. H. Weidle, and W. Kolch The role of MAPK pathways in the action of chemotherapeutic drugs Carcinogenesis, November 1, 2002; 23(11): 1831 - 1838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Peitsaro, B. Johansson, and S. Syrjanen Integrated Human Papillomavirus Type 16 Is Frequently Found in Cervical Cancer Precursors as Demonstrated by a Novel Quantitative Real-Time PCR Technique J. Clin. Microbiol., March 1, 2002; 40(3): 886 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. RHIM Development of Human Cell Lines from Multiple Organs Ann. N.Y. Acad. Sci., September 1, 2000; 919(1): 16 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. M. CHEN Replicative Senescence and Oxidant-Induced Premature Senescence: Beyond the Control of Cell Cycle Checkpoints Ann. N.Y. Acad. Sci., June 1, 2000; 908(1): 111 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Schønning, M. Bévort, S. Mikkelsen, M. Andresen, P. Thomsen, H. Leffers, and B. Norrild Human papillomavirus type 16 E7-regulated genes: regulation of S100P and ADP/ATP carrier protein genes identified by differential-display technology J. Gen. Virol., April 1, 2000; 81(4): 1009 - 1015. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. P. TOY, L. RODRIGUEZ-RODRIGUEZ, D. MCCANCE, J. LUDLOW, and V. PLANELLES Induction of Cell-Cycle Arrest in Cervical Cancer Cells by the Human Immunodeficiency Virus Type 1 Viral Protein R Obstet. Gynecol., January 1, 2000; 95(1): 141 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Braunstein, B. S. Madsen, B. Gavnholt, M. W. Rosenstierne, C. Koefoed Johnsen, and B. Norrild Identification of a new promoter in the early region of the human papillomavirus type 16 genome J. Gen. Virol., December 1, 1999; 80(12): 3241 - 3250. [Abstract] [Full Text]
|
|
|
|
|
|
M. Yoshinouchi, A. Hongo, K. Nakamura, J. Kodama, S. Itoh, H. Sakai, and T. Kudo Analysis by Multiplex PCR of the Physical Status of Human Papillomavirus Type 16 DNA in Cervical Cancers J. Clin. Microbiol., November 1, 1999; 37(11): 3514 - 3517. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Swan, R. A. Tucker, G. Tortolero-Luna, M. F. Mitchell, L. Wideroff, E. R. Unger, R. A. Nisenbaum, W. C. Reeves, and J. P. Icenogle Human Papillomavirus (HPV) DNA Copy Number Is Dependent on Grade of Cervical Disease and HPV Type J. Clin. Microbiol., April 1, 1999; 37(4): 1030 - 1034. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Lu and M. Danielsen Differential Regulation of Androgen and Glucocorticoid Receptors by Retinoblastoma Protein J. Biol. Chem., November 20, 1998; 273(47): 31528 - 31533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Zacny, J. Wilson, and J. S. Pagano The Epstein-Barr Virus Immediate-Early Gene Product, BRLF1, Interacts with the Retinoblastoma Protein during the Viral Lytic Cycle J. Virol., October 1, 1998; 72(10): 8043 - 8051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Goodwin, L. K. Naeger, D. E. Breiding, E. J. Androphy, and D. DiMaio Transactivation-Competent Bovine Papillomavirus E2 Protein Is Specifically Required for Efficient Repression of Human Papillomavirus Oncogene Expression and for Acute Growth Inhibition of Cervical Carcinoma Cell Lines J. Virol., May 1, 1998; 72(5): 3925 - 3934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Ozbun and C. Meyers Temporal Usage of Multiple Promoters during the Life Cycle of Human Papillomavirus Type 31b J. Virol., April 1, 1998; 72(4): 2715 - 2722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Lowy and J. T. Schiller Papillomaviruses and Cervical Cancer: Pathogenesis and Vaccine Development J Natl Cancer Inst Monographs, April 1, 1998; 1998(23): 27 - 30. [Abstract] [Full Text]
|
|
|
|
|
|
S.-S. Kim, J. K. Tam, A.-F. Wang, and R. S. Hegde The Structural Basis of DNA Target Discrimination by Papillomavirus E2 Proteins J. Biol. Chem., September 29, 2000; 275(40): 31245 - 31254. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
